|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/28/12 Ziopharm Oncology Inc 10-Q/A 6/30/12 50:3.1M Toppan Merrill/FA |
Document/Exhibit Description Pages Size
1: 10-Q/A Amendment to Quarterly Report HTML 29K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 20K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 20K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 18K
32: R1 Document and Entity Information HTML 37K
23: R2 Balance Sheets HTML 112K
30: R3 Balance Sheets (Parenthetical) HTML 39K
34: R4 Statements Of Operations HTML 67K
46: R5 Statement Of Stockholders' Equity HTML 66K
24: R6 Statement Of Stockholders' Equity (Parenthetical) HTML 18K
29: R7 Statements of Cash Flows HTML 142K
21: R8 Business HTML 26K
15: R9 Summary of Significant Accounting Policies HTML 19K
47: R10 Collaborations and Alliances HTML 21K
36: R11 Fair Value Measurements HTML 38K
35: R12 Net Loss per Share HTML 23K
40: R13 Related Party Transactions HTML 22K
41: R14 Commitments and Contingencies HTML 53K
39: R15 Warrants HTML 52K
42: R16 Common Stock HTML 19K
31: R17 Stock-Based Compensation HTML 48K
33: R18 Fair Value Measurements (Tables) HTML 27K
38: R19 Net Loss per Share (Tables) HTML 22K
50: R20 Warrants (Tables) HTML 42K
44: R21 Stock-Based Compensation (Tables) HTML 52K
26: R22 Business - Additional Information (Detail) HTML 23K
37: R23 Collaborations and Alliances - Additional HTML 24K
Information (Detail)
28: R24 Assets and Liabilities Measured at Fair Value on HTML 26K
Recurring Basis (Detail)
13: R25 Potential Dilutive Shares Excluded from HTML 26K
Computation of Diluted Net Loss Per Share (Detail)
45: R26 Related Party Transactions - Additional HTML 28K
Information (Detail)
48: R27 Commitments and Contingencies - Additional HTML 121K
Information (Detail)
18: R28 Number of Warrants Outstanding (Detail) HTML 21K
17: R29 Warrants - Additional Information (Detail) HTML 74K
19: R30 Assumptions Used In Binomial Valuation Model and HTML 25K
Black-Scholes Valuation Model (Detail)
20: R31 Warrant Exercise (Detail) HTML 32K
22: R32 Common Stock - Additional Information (Detail) HTML 34K
11: R33 Stock-Based Compensation Expense on All Employee HTML 23K
and Non-Employee Awards (Detail)
43: R34 Stock-Based Compensation - Additional Information HTML 31K
(Detail)
25: R35 Fair Value of Stock Options Assumptions Using HTML 34K
Black-Scholes Option Valuation Model (Detail)
27: R36 Stock Option Activity Under Stock Option Plan HTML 83K
(Detail)
14: R37 Summary of Unvested Restricted Stock (Detail) HTML 46K
49: XML IDEA XML File -- Filing Summary XML 74K
16: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 392K
5: EX-101.INS XBRL Instance -- ziop-20120630 XML 731K
7: EX-101.CAL XBRL Calculations -- ziop-20120630_cal XML 109K
8: EX-101.DEF XBRL Definitions -- ziop-20120630_def XML 650K
9: EX-101.LAB XBRL Labels -- ziop-20120630_lab XML 966K
10: EX-101.PRE XBRL Presentations -- ziop-20120630_pre XML 726K
6: EX-101.SCH XBRL Schema -- ziop-20120630 XSD 147K
12: ZIP XBRL Zipped Folder -- 0001144204-12-048414-xbrl Zip 101K
EXHIBIT 31.1
CERTIFICATION
I, Jonathan Lewis, certify that:
1. I have reviewed this quarterly report on Form 10-Q of ZIOPHARM Oncology, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: August 28, 2012
| /s/ Jonathan Lewis |
|
Jonathan Lewis, M.D., Ph.D. Chief Executive Officer |
| (Principal Executive Officer) |
C:
| This ‘10-Q/A’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/28/12 | |||
| For Period end: | 6/30/12 | 10-Q | ||
| List all Filings | ||||